Sex and racial disparities in clinical outcomes and health resource use among patients with primary biliary cholangitis in the United States Julius M Wilder, Hongbo Yang, Su Zhang, Dongni Ye, Sherry Shi, Anyu Zhu, Ashley Jowell, Larissa Lushniak, Nisreen Shamseddine Abstract AbstractBackground:Racial and sex disparities have been described in liver conditions, including primary biliary cholangitis (PBC). This study sought to understand how race/ethnicity and sex-based differences impact access to diagnosis, clinical outcomes, health resource use (HRU), and treatment among patients with PBC in the United States (US).Methods:Komodo Research Database claims data (2016–2023) for adults diagnosed with PBC were analyzed retrospectively. Patients were grouped by race/ethnicity (White, Black, Hispanic, Asian, and Other) and separately by sex (male or female). Clinical characteristics, treatment patterns, and HRU outcomes were assessed pre-index and post-index. The index date was defined as the first claim with a PBC diagnosis code. Statistical significance for comparisons was defined as p<0.05.Results:In total, 9554 and 11,591 patients were included in the race/ethnicity and sex analyses. Black and Hispanic patients (versus [vs.] White) and male patients (vs. female) had higher comorbidity burden and PBC-related symptoms pre-index. Post-index, Black patients (vs. White) had significantly higher risks of liver transplant and hospitalization due to hepatic decompensation (adjusted hazard ratio [HR] of 2.09 and 1.37, respectively). Hispanic patients (vs. White) had a significantly higher risk of developing cirrhosis (adjusted HR of 1.19). Males had a higher risk than females for all adverse outcomes. Most HRU outcomes were significantly higher for Black patients vs. White, while treatment rates and response rates to ursodeoxycholic acid were significantly lower for Black patients vs. White and male patients vs. female.Conclusions:These results highlight significant differences in disease management and treatment initiation across race/ethnicity and sex groups in the US. Improved provider awareness of such differences in PBC is required to support individualized management and ensure equitable access to PBC treatment.Keywords: cohort studies, health disparities, liver diseases, rare diseases, real-world data, retrospective studies [hc9-10-e1030-g001.webp][hc9-10-e1030-g001.gif] INTRODUCTION Primary biliary cholangitis (PBC) is a rare cholestatic liver disease that predominantly affects women aged 40–60 years.– PBC is characterized by the autoimmune destruction of intrahepatic bile ducts, which can progress to cirrhosis, the need for liver transplantation (LT), and/or premature death if left untreated., Timely diagnosis and treatment of PBC is important since it can prevent or delay disease progression. To date, ursodeoxycholic acid (UDCA) is the recommended first-line (1L) treatment for patients with PBC per the 2017 European Association for the Study of the Liver (EASL) and the 2018 American Association for the Study of Liver Diseases (AASLD) treatment guidelines., Although some patients show liver biochemistry improvements following treatment, up to 40% do not achieve adequate response to UDCA,, and 3%–5% of patients are intolerant. The United States (US) Food and Drug Administration (FDA) has approved second-line treatments: obeticholic acid (OCA) and 2 proliferator-activated receptor agonists, elafibranor and seladelpar (approved on June 10, 2024, and August 14, 2024, respectively).– However, OCA was voluntarily withdrawn from the US market in September 2025 at the FDA’s request. Fibrates have been used as an off-label treatment for patients with an incomplete response to UDCA per the 2018 AASLD guideline recommendations; however, their use is contraindicated for patients with decompensated liver disease., In the US, the estimated prevalence of PBC is 40.9 per 100,000 persons. Women are more commonly affected than men (approximately 9:1) according to recent epidemiological studies, although estimates vary. PBC affects all races and ethnicities, while White patients are disproportionately more likely to be diagnosed, prevalence of diagnosis is increasing among other groups in the US, including Black and Asian individuals., The US has a diverse population, and racial and ethnic disparities in health outcomes are well documented. A 2025 systematic literature review by Faugno et al that included studies of patients across various health conditions found that patients from underserved racial and ethnic groups in the US (specifically Black, Native American/Alaskan Native, Hispanic, and Latino patients) encountered barriers to timely diagnosis stemming from socioeconomic and sociocultural factors (eg, trust in the health care system, health literacy barriers), provider-level factors (eg, cognitive biases, culturally sensitive communication), and health systems factors (eg, inequity in organizational health literacy, lack of cultural competence). Race/ethnic and sex-based health disparities have previously been described in liver conditions, including PBC. Clinical trials in PBC are predominantly composed of White female patients; in 2 recent phase 3 trials investigating elafibranor and seladelpar, approximately 90% of participants were White and >90% were female., Male patients and patients from racial/ethnic groups that have been considered minority populations in the US, including Black or African American, Hispanic or Latino, and Asian patients, are not well represented in clinical trials despite also being affected by PBC. A previous study found that among patients with PBC on a LT waitlist, Hispanic patients had lower LT rates and a significantly higher risk of death than White patients. Previous studies also found that Hispanic patients had higher hospitalization rates and that Black patients had a higher in-hospital mortality rate than White patients., Limited but heterogenous data on PBC presentation and prognosis across sexes have also been reported in published literature. In some studies, male sex was a risk factor for mortality in PBC and associated with more advanced disease at presentation, poor response to 1L UDCA treatment, increased hepatocellular carcinoma (HCC) risk, and delayed diagnosis.– In addition, a US real-world study of UDCA treatment found that men were significantly less likely than women to receive treatment, and African American patients were significantly less likely to receive treatment than White patients. However, other publications found no significant sex-based differences in outcomes or laboratory measures in PBC., These studies had limitations, including the use of historical data (collected ≥5 years to present day), non-US populations, and small sample sizes. Therefore, there is a need to understand updated racial, ethnic, and sex-based disparities in PBC diagnosis and treatment. Greater provider education on inequities in treatment may lead to individualized management and equitable access to PBC treatment. Real-world evidence, including claims-based data, provides timely and representative insights into PBC care and clinical outcomes in the US and can be used to address this evidence gap and inform clinical decision-making. The objective of this study was to understand how race/ethnicity and sex affect access to care, health care utilization, and clinical outcomes in PBC by conducting a retrospective analysis of the US claims data linked with laboratory data. This study is among the first to evaluate both race/ethnicity and sex disparities in PBC care and management. METHODS Study design This observational, retrospective cohort study analyzed claims data from January 2016 to September 2023 using the Komodo Research Database (KRD+). The KRD+ contains administrative claims data on more than 330 million patients enrolled in US health care plans, including commercial, Medicare Advantage, and Medicaid managed care plans. Adult patients aged 18 years or above with a PBC diagnosis on or after January 1, 2017 were identified based on the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code K74.3. Patients were included if they had continuous enrollment in the database for ≥12 months before the first observed PBC diagnosis code and ≥1 month after that date, had not received LT or OCA before the first observed PBC diagnosis code, and had available race/ethnicity information (for the race/ethnicity analysis) or sex information (for the sex analysis). The index date was the date of the first claim associated with an ICD-10-CM code for PBC in the available data. The baseline period (pre-index) was defined as 12 months before the index date. The follow-up period was defined as time from index date to the earliest of death, end of continuous enrollment, or KRD+ data cutoff (henceforth referred to as post-index; Supplemental Figure S1, https://links.lww.com/HC9/C457). A cohort selection flowchart with sample selection criteria is presented in Supplemental Figure S2, https://links.lww.com/HC9/C457. To assess race/ethnic disparities, eligible patients with race/ethnic group information were classified into 5 mutually exclusive cohorts as pre-defined in the KRD+: White, Black or African American (henceforth referred to as Black), Hispanic or Latino (henceforth referred to as Hispanic), Asian and Pacific Islanders (henceforth referred to as Asian), and other race/ethnic groups (henceforth referred to as Other). The race/ethnicity classification in the KRD+ used data from patients who had an outpatient (OP), inpatient (IP), or emergency room (ER) visit and who chose to report race/ethnicity. To assess sex disparities, eligible patients were classified as males and females based on biological sex, as reported in the KRD+. Study outcomes and statistical analysis Patient characteristics, including patient demographics and clinical characteristics (comorbidities, PBC-related symptoms/complications, liver diseases resembling PBC, and health resource use [HRU] per-patient-per-year [PPPY]), were assessed during the pre-index period (Table ). Comorbidities, PBC-related symptoms/complications, and liver diseases resembling PBC were determined using the ICD-10-CM diagnosis codes listed (Supplemental Table S1, https://links.lww.com/HC9/C457). These outcomes were descriptively summarized for each race/ethnicity group and for males and females, separately. Mean, standard deviation (SD), and range were used for continuous variables and counts and percentages (95% confidence interval [CI]) for categorical variables. Univariable comparisons were conducted to compare each non-White cohort versus (vs.) the White cohort and to compare males vs. females, respectively. t Test or Wilcoxon rank-sum test was conducted for continuous variables, and χ2 tests were conducted for categorical variables. Multiple outcomes were assessed during the post-index period, including time to adverse clinical outcomes, time to first PBC treatment initiation (UDCA, OCA, and fibrates [fenofibrate or gemfibrozil]), all-cause HRU, time to specialist visits (visit to a hepatologist or gastroenterologist), and treatment response rate. PBC-related treatments were determined using the National Drug Code (Supplemental Table S2, https://links.lww.com/HC9/C457). Post-index adverse clinical outcomes of PBC included cirrhosis, clinically significant portal hypertension, hepatic decompensation, hospitalization due to hepatic decompensation, end-stage liver disease, HCC, LT, and death. These adverse clinical outcomes were identified using ICD-10-CM diagnosis codes provided in Supplemental Table S1, https://links.lww.com/HC9/C457. Time to each adverse clinical outcome and time to the earliest adverse clinical outcome (ie, earliest of any of the outcomes listed above) were evaluated using Kaplan-Meier (KM) analysis in patients who were free of the respective outcome during the pre-index period, with results stratified by cohort based on race/ethnicity (for the race/ethnicity analysis) and based on sex (for the sex analysis). Unadjusted log-rank tests were used to compare time-to-event outcomes across study groups. For adjusted time-to-event analyses, multivariable Cox proportional hazard (PH) models were used to adjust for baseline covariates that are potential confounders. Confounders were identified based on assessment of clinical relevance, statistical significance in baseline univariable comparisons, and the associated sample size (see Tables and for the list of confounders). For adverse clinical outcomes, Cox PH models were fitted to estimate HRs comparing each non-White cohort vs.the White cohort and comparing males vs.females, with and without adjusting for key baseline characteristics. Time to first PBC treatment initiation post-index was evaluated using the same approach as described above for time to adverse clinical outcomes: KM analyses with log-rank tests were applied for unadjusted comparisons, and multivariable Cox PH models adjusting for baseline covariates were used for the adjusted comparisons. All-cause HRU post-index included the number of medical visits (including number of IP admissions, OP admissions, and ER visits), IP lengths of stay, number of liver functional lab tests, and time to specialist visits. PBC-related lab tests were determined from the KRD+ data using Current Procedural Terminology/Healthcare Common Procedure Coding System and ICD-10 Procedure Coding System provided in Supplemental Table S3, https://links.lww.com/HC9/C457. HRU outcomes were examined on a PPPY basis, and generalized linear models with and without controlling key baseline characteristics were fitted to estimate incidence rate ratios (IRRs). Time to specialist visits was evaluated using the same approach as described above for time to adverse clinical outcomes. Patients who visited specialists during the pre-index period were included in this analysis, with the event date being the index date. Treatment response rate to 1L UDCA treatment was estimated in each cohort and was compared between each non-White cohort vs.the White cohort and between male and female patients. Inadequate response was defined as second-line treatment initiation (OCA or fibrates) within 12 months of UDCA initiation or failure to meet lab-based response criteria: the modified Toronto criteria (alkaline phosphatase [ALP] ≤1.67x upper limit of normal [ULN]) or the modified Primary Biliary Cholangitis to Improve Survival Estimation (POISE) criteria (ALP <1.67x ULN and bilirubin